Abstract
Craniofacial bone structures are frequently and extensively affected by trauma, tumors, bone infections and diseases, age-related degeneration and atrophy, as well as congenital malformations and developmental anomalies. Consequently, severe encumbrances are imposed on both patients and healthcare systems due to the complex and lengthy treatment duration. The search for alternative methods to bone transplantation, grafting and the use of homologous or heterologous bone thus responds to one of the most significant problems in human medicine. This review focuses on the current consensus of bone-tissue engineering in the craniofacial area with emphasis on drug-induced stem cell differentiation and induced bone regeneration.
Acknowledgements
The authors wish to express their gratitude to Dr Marinella Ringe for editorial assistance.
Declaration of interest
The authors report no declaration of interest. Dr Ondine Lucaciu work was (partially) financed by POSDRU grant no. 159/1.5/S/136893 grant with title: “Strategic partnership for scientific research improvement, in medical schools through doctoral and post-doctoral scholarships – DocMed.Net_2.0”.